{
  "docId": "019de074-5234-763a-a0be-96f5f1aa05d9",
  "docSlug": "9279d19020d2e95032dc34a127aaa2e7",
  "documentTitle": "Compass Therapeutics | Investor Presentation Deck | 40 slides",
  "authorId": "compass-therapeutics",
  "authorName": "Compass Therapeutics",
  "documentKindSlug": "pitchdeck",
  "documentKindLabel": "Pitch deck",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2023-02-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 28,
  "pageCount": 40,
  "prevPage": 27,
  "nextPage": 29,
  "slideType": "roadmap",
  "function": "plan_implementation",
  "density": "balanced",
  "nDataPoints": 0,
  "notes": "The slide uses a three-column layout to represent sequential or parallel development tracks.",
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de074-5234-763a-a0be-96f5f1aa05d9/28",
  "deckHref": "/decks/019de074-5234-763a-a0be-96f5f1aa05d9",
  "deckJsonHref": "/decks/019de074-5234-763a-a0be-96f5f1aa05d9.json",
  "deckAnchorHref": "/decks/019de074-5234-763a-a0be-96f5f1aa05d9#slide-28",
  "components": [
    {
      "bbox": {
        "h": 0.585,
        "w": 0.223,
        "x": 0.37,
        "y": 0.235
      },
      "kind": "list",
      "text": "Initiate Q1 2023: Phase 2/3 Randomized BTC study in the US",
      "attrs": null,
      "subkind": "timeline-item",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "1c4d70e4-968d-44ec-baa7-2271c258f96b",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.585,
        "w": 0.223,
        "x": 0.071,
        "y": 0.235
      },
      "kind": "list",
      "text": "Initiated Q4 2022: Phase 2 study in third- and fourth-line colorectal cancer in the US",
      "attrs": null,
      "subkind": "timeline-item",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "92bb061e-dd8d-43a3-9405-9d09fa728892",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.585,
        "w": 0.223,
        "x": 0.662,
        "y": 0.235
      },
      "kind": "list",
      "text": "Initiate H2 2023: Phase 2 study in advanced ovarian or other cancer in the US",
      "attrs": null,
      "subkind": "timeline-item",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "fd2bcfb4-1171-4bd5-b117-9672ec8d5593",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.035,
        "w": 0.948,
        "x": 0.052,
        "y": 0.825
      },
      "kind": "paragraph",
      "text": "Evaluating additional indications for CTX-009 both as a monotherapy and in combination with chemotherapy",
      "attrs": null,
      "subkind": "paragraph",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "0141d416-1b71-4b01-8547-c03578bdef53",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.045,
        "w": 0.424,
        "x": 0.034,
        "y": 0.078
      },
      "kind": "title",
      "text": "CTX-009 Development Plans",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "5583e8dd-be2f-4eaf-8d20-a0ac1c35bad6",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [],
  "frameworks": [
    {
      "name": "gantt-chart",
      "slug": null,
      "matchId": "8fc90b21-9144-4d1b-a3f4-7ab56a74b027",
      "evidence": "The slide presents a timeline of development activities across different tracks.",
      "confidence": 0.7
    }
  ],
  "arcBeats": [],
  "loops": [
    {
      "to": 40,
      "from": 3,
      "name": "Cost Of Inaction",
      "slug": "27-cost-of-inaction",
      "bestFor": "Urgent budget requests, compliance, risk mitigation",
      "matchId": "f0a32b3c-a238-480c-9a9d-c05166154467",
      "evidence": "The document implies that the current state of cancer treatment is inadequate and that innovative therapies are needed.",
      "position": 0,
      "objective": "The cost of inaction in cancer treatment",
      "structure": "The Status Quo -> The Hidden Costs Accumulating -> The Future State of Inaction -> The Tipping Point",
      "confidence": 0.6,
      "description": "Quantify what happens if the audience does nothing"
    },
    {
      "to": 40,
      "from": 7,
      "name": "Pattern Hunter",
      "slug": "02-pattern-hunter",
      "bestFor": "Time-pressed audiences, building consensus, when data is strong",
      "matchId": "6979bcd9-f71b-4757-b297-1c4753563587",
      "evidence": "The document presents data and results for each of these therapies.",
      "position": 1,
      "objective": "The potential benefits of CTX-009, CTX-471, and CTX-8371",
      "structure": "Evidence A -> Evidence B -> Evidence C -> Pattern/Conclusion",
      "confidence": 0.6,
      "description": "Group multiple pieces of evidence that together point to a pattern or conclusion"
    }
  ],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}